PHP
XFOR icon

Parkman Healthcare Partners’s X4 Pharmaceuticals XFOR Stock Holding History

Parkman Healthcare Partners’s Portfolio XFOR Stock Details XFOR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q4 		– Sell
-27,291
Closed -$548K – 101
2024
Q3 		$548K Buy
27,291
+404
+2% +$8.43K 0.07% 89
2024
Q2 		$468K Buy
26,887
+42
+0.2% +$1.37K 0.06% 87
2024
Q1 		$1.12M Buy
26,845
+1,267
+5% +$35.3K 0.14% 91
2023
Q4 		$643K Sell
25,578
-1,089
-4% -$26.5K 0.09% 86
2023
Q3 		$872K Sell
26,667
-98,886
-79% -$4.31M 0.16% 92
2023
Q2 		$7.31M Buy
125,553
+32,315
+35% +$1.66M 1.27% 26
2023
Q1 		$2.43M Buy
93,238
+14,053
+18% +$412K 0.53% 52
2022
Q4 		$2.36M Buy
79,185
+47,518
+150% +$2.25M 0.63% 53
2022
Q3 		$1.63M Buy
+31,667
New +$1.09M 0.46% 63

Other funds holding XFOR

BCLSI
Bain Capital Life Sciences Investors Boston, Massachusetts $1.68B AUM 126.09% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
ACA
Acorn Capital Advisors New York $366M AUM 474.6% 1-Year Est. Return
O
OrbiMed New York $5.4B AUM 163.13% 1-Year Est. Return
KCM
Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
Axa
Axa Paris, France $91.9M AUM 27.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Parkman Healthcare Partners's XFOR Position: Q4 2024 in Review

Parkman Healthcare Partners sold out of X4 Pharmaceuticals (XFOR) in Q4 2024, closing a stake of 27,291 shares — an estimated $548K sold.

Parkman Healthcare Partners first reported a position in XFOR in Q3 2022 and held it in 9 quarters. The position peaked at $7.31M in Q2 2023. 89 funds tracked by Wall St. Rank hold XFOR as of Q4 2024.

  • Parkman Healthcare Partners reported no remaining X4 Pharmaceuticals position as of Q4 2024 after selling out during the quarter.
  • Parkman Healthcare Partners sold 27,291 X4 Pharmaceuticals shares in Q4 2024, an estimated $548K.
  • Parkman Healthcare Partners first reported a position in X4 Pharmaceuticals in Q3 2022 and held it in 9 quarters.
  • Parkman Healthcare Partners's X4 Pharmaceuticals position peaked at $7.31M in Q2 2023.
  • 89 funds tracked by Wall St. Rank held X4 Pharmaceuticals as of Q4 2024.

Based on Parkman Healthcare Partners's 13F filing for Q4 2024, filed 14 Feb 2025.